Literature DB >> 3769220

Malignant hypertension: aetiology and outcome in 83 patients.

S H Yu, J A Whitworth, P S Kincaid-Smith.   

Abstract

To evaluate the current pattern of aetiology and outcome in malignant hypertension, we reviewed all medical records of patients presenting between 1979 and 1985 who fulfilled WHO criteria for malignant hypertension. There were 83 patients, 43 males (52%) and 40 females (48%). Primary malignant hypertension was diagnosed in 17 cases (20%) and secondary lesions in 66 cases (80%). Overall one year survival was 94%, and 5 year survival 75%, which is similar to recent reports. Initial serum creatinine was a prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769220     DOI: 10.3109/10641968609045483

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  6 in total

1.  "Hypertensive emergency": a useful diagnostic category.

Authors:  R B Hickler
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

2.  A case of systemic lupus erythematosus presenting as malignant hypertension with hypertensive retinopathy.

Authors:  Jung-Yoon Choe; Sung-Hoon Park; Ji-Young Kim; Hyun-Young Jung; Seong-Kyu Kim
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

Review 3.  Secondary hypertension. An overview of its causes and management.

Authors:  D H Streeten; G H Anderson
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

4.  A 10-year Study: Renal Outcomes in Patients with Accelerated Hypertension and Renal Dysfunction.

Authors:  Aleya Anitha; Kishore Babu
Journal:  Indian J Nephrol       Date:  2020-11-07

Review 5.  Malignant Hypertension and the Role of Ophthalmologists: A Review Article.

Authors:  Priyadarshini Mishra; Nikita Dash; Sandip K Sahu; Vikas Kanaujia; Kumudini Sharma
Journal:  Cureus       Date:  2022-07-22

Review 6.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.